<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10408850</article-id><article-id pub-id-type="pmc">2362341</article-id><article-id pub-id-type="pii">6690375</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Okada</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sakata</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Matsuno</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kurihara</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ohashi</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Taguchi</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><collab>for the Cooperative Group of Docetaxel for Pancreatic Cancer in Japan</collab></contrib><aff id="aff1">Department of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan</aff><aff id="aff2">Department of Gastroenterology and Endoscopy, Aomori Prefectural Central Hospital, 2-1-1 Higashi Tsukurimichi, Aomori-shi, Aomori, 030-0913, Japan</aff><aff id="aff3">Department of Surgery I, Tohoku University School of Medicine, 2-1 Seiryocho, Aoba-ku, Sendai-shi, Miyagi, 980-0873, Japan</aff><aff id="aff4">Department of Gastroenterology, Toyosu Hospital, Showa University, 4-1-18 Toyosu, Koto-ku, Tokyo, 135-8577, Japan</aff><aff id="aff5">Department of Oncology/Hematology and Clinical Pharmacology, National Cancer Hospital East, 6-5-1 Kashiwanoha, Kashiwa-sh, Chiba, 277-0882, Japan</aff><aff id="aff6">Department of Epidemiology and Biostatistics, School of Health Science and Nursing, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan</aff><aff id="aff7">Japan Society for Cancer Chemotherapy, 1-18-35 Edobori, Osaka, 550-0014, Japan</aff></contrib-group><pub-date pub-type="ppub"><month>5</month><year>1999</year></pub-date><pub-date pub-type="epub"><day>01</day><month>05</month><year>1999</year></pub-date><volume>80</volume><issue>3-4</issue><fpage>438</fpage><lpage>443</lpage><history><date date-type="received"><day>08</day><month>07</month><year>1998</year></date><date date-type="rev-recd"><day>13</day><month>11</month><year>1998</year></date><date date-type="accepted"><day>20</day><month>11</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Docetaxel has been reported to show promising anti-tumour activity in pancreatic ductal cancer (PC). This study was conducted to evaluate the activity and toxicity of moderate-dose (60 mg m<sup>&#x02212;2</sup>) docetaxel in Japanese chemo-naive patients with measurable metastatic PC. The patients had a performance status of 0&#x02013;2. They received docetaxel intravenously over a 1- to 2-h period without any premedication for hypersensitivity reactions. This treatment was repeated every 3&#x02013;4 weeks with dose adjustments based on the toxic effects observed. Twenty-one patients were eligible and treated with docetaxel. The median number of courses was 2 (range, 1&#x02013;4). None of the patients achieved an objective response; seven showed no change and 13 showed progressive disease. In one patient, the response was not assessable because of early death. The median survival time for all patients was 118 days. The main grade 3&#x02013;4 toxicities by patient were leucocytopenia (67&#x00025;) and neutropenia (86&#x00025;). Other grade 3&#x02013;4 toxicities included anaemia (10&#x00025;), thrombocytopenia (5&#x00025;), nausea/vomiting (29&#x00025;), anorexia (29&#x00025;), GOT/GPT increase (10&#x00025;), alkaline phosphatase increase (14&#x00025;), malaise/fatigue (33&#x00025;) and alopecia (24&#x00025;). In conclusion, docetaxel, administered on this schedule, did not show significant anti-tumour activity in patients with metastatic PC. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>docetaxel</kwd><kwd>chemotherapy</kwd><kwd>pancreatic cancer</kwd><kwd>phase II study</kwd></kwd-group></article-meta></front></article>
